MERS is an illness caused by a virus called Middle East Respiratory Syndrome Coronavirus (MERS-CoV). MERS affects the respiratory system (lungs and breathing tubes), and most MERS patients will develop severe acute respiratory illness with symptoms of fever, cough and shortness of breath, with a death rate of 30%.
This virus is known to spread from ill people to others through close contact and all of the cases in South Korea have been linked to exposure to MERS-CoV in a hospital or clinic suggesting that there is no evidence of sustained community transmission. However, it is widely recognized that MERS-CoV has the potential to cause global outbreaks, and as such, the need for an accurate and reliable test for surveillance and detection is essential.
To meet this need, Veredus offers a new solution: VereMERS™. With the flexibility of updating our VereMERS™ chip to include the detection of newly mutated strains, this Lab-on-Chip application, together with the VerePLEX™ Lab-on-Chip platform, makes MERS surveillance and diagnostics possible with the right coverage of detection when mutation occurs.
For Research Use Only. Not for use in diagnostic procedures.
Detection of NS3 and S target genes with multiple probes to positively identify MERS-CoV
Process Controls on each chip:
- PCR: Positive Control
- Hybridization: Orientation Probes, Positive Control Probes, Negative Control
Sample Types*: serum and respiratory swabs (nasopharyngeal, oropharyngeal, throat, nasal or throat aspirates)
*As recommended by World Health Organization (WHO)
- RNA samples to results in less than 2.5 hours
- Detection of NS3 and S genes for MERS-CoV surveillance and enables prompt action by healthcare authorities to control MERS-CoV outbreaks
- Detects only MERS-CoV and no cross-reactivity with other coronaviruses such as OC43, 229E, KHU1, NL63
- Targets NS3 and S genes with multiple probes and duplicates.
- The VerePLEXTM Biosystem is designed to be portable for usage at areas such as checkpoints and borders.
Easy to use
- The simple workflow allows for minimally trained or non-scientific personnel to run tests
- Probes can be updated quickly to include new mutations of the evolving MERS-CoV and ensure the right coverage of detection
- Multiplex amplification reactions
- Multiple probes per target ensures reliable detection
- Small sample volume requirement
- Fast and programmable temperature ramp rate
- Scalable for high throughput
- PCR yield is comparable to standard thermal cyclers
- Functional validation of hybridization for each assay is provided by an internal positive hybridization control
- Proprietary microfluidic interface: contact surfaces are biocompatible and do not inhibit the PCR reaction
- Short time required for fluidic operations